xbrane corporate presentation

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E:

Invitation to presentation of Xbrane Biopharma’s Year-end report 2023 on February 26, 2024

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on Monday, February 26th, 2024, at 13.00 a.m. CET. Xbrane will publish the company’s Year-end report 2023, on Monday, February 26, 2024, at 8.00 a.m. CET.

Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, will present the interim Year-end report 2023, followed by a Q&A session. The presentation will be in English.

If you wish to participate via webcast, please use the link below. Via the webcast you can ask written questions. Xbrane Biopharma Q4 Report 2023 (financialhearings.com)

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference. Call Access (financialhearings.com)

Martin Åmark, CEO M: +46 76 309 37 77 E: [email protected]

Anette Lindqvist, CFO/IR M: +46 76 325 60 90 E: [email protected]

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 27 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during the first quarter 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit  www.xbrane.com  

Attachments

• Get 7 Days Free

Xbrane Biopharma AB XBRANE

About quantitative ratings.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

Trading information, key statistics, company profile, comparables.

• Calliditas Therapeutics AB CALTX
• SynAct Pharma AB SYNACT
• Hansa Biopharma AB HNSA

Financial Strength

Profitability

Biotechnology Industry Comparables

Sponsor Center

Xbrane Biopharma Investor Relations Material

• Xbrane Biopharma

Latest events

Partnership

Latest reports from xbrane biopharma, key slides for xbrane biopharma.

Latest articles

How the Birkin bag became the world's most sought-after handbag where even the wealthy must earn the right to own one.

Discover the top 10 semiconductor companies by market cap, exploring their innovations and business models shaping the tech landscape.

Discover how Nubank revolutionized Latin American banking with innovation, backed by top investors like Berkshire Hathaway.

THE BEST Elektrostal Art Museums

Art museums in elektrostal.

• Specialty Museums
• Art Museums
• History Museums
• 4.0 of 5 bubbles & up
• Good for Kids
• Good for Big Groups
• Adventurous
• Budget-friendly
• Good for a Rainy Day
• Hidden Gems
• Good for Couples
• Honeymoon spot
• Good for Adrenaline Seekers
• Things to do ranked using Tripadvisor data including reviews, ratings, number of page views, and user location.

1. Electrostal History and Art Museum

Post comment

or continue as guest

English (USA)

English (UK)

English (Canada)

English (India)

Deutsch (Deutschland)

Deutsch (Österreich)

Deutsch (Schweiz)

Français (France)

Français (Suisse)

Nederlands (Nederland)

Nederlands (België)

• Top Capitalization
• United States
• North America
• Middle East
• Sector Research
• Earnings Calendar
• Equities Analysis
• Most popular
• NIPPON ACTIVE VALUE FUND PLC
• INFINEON TECHNOLOGIES AG
• NVIDIA CORPORATION
• META PLATFORMS, INC.
• INTEL CORPORATION
• AMAZON.COM, INC.
• Index Analysis
• Indexes News
• EURO STOXX 50
• Currency Cross Rate
• Currency Converter
• Forex Analysis
• Currencies News
• Precious metals
• Agriculture
• Industrial Metals
• Livestock and Cattle
• CRUDE OIL (WTI)
• CRUDE OIL (BRENT)

• Yield Curve
• Developed Nations
• Emerging Countries
• South America
• Analyst Reco.
• Capital Markets Transactions
• New Contracts
• Profit Warnings
• Appointments
• Press Releases
• Security Transactions
• Earnings reports
• New markets
• New products
• Corporate strategies
• Legal risks
• Share buybacks
• Mergers and acquisitions
• Call Transcripts
• Currency / Forex
• Commodities
• Cryptocurrencies
• Interest Rates
• Asset Management
• Climate and ESG
• Cybersecurity
• Geopolitics
• Central Banks
• Private Equity
• Business Leaders
• All our articles
• Most Read News
• All Analysis
• Satirical Cartoon
• Today's Editorial
• Crypto Recap
• Behind the numbers
• All our investments
• Asia, Pacific
• Virtual Portfolios
• USA Portfolio
• European Portfolio
• Asian Portfolio
• My previous session
• My most visited
• Quality stocks at a reasonable price
• Dividend Aristocrats
• Growth stocks at reasonable prices
• Quality stocks
• Momentum stocks
• Millennials
• Powerful brands
• Israeli innovation
• Oligopolies
• Artificial Intelligence
• Unusual volumes
• New Historical Highs
• New Historical Lows
• Top Fundamentals
• Sales growth
• Earnings Growth
• Profitability
• Rankings Valuation
• Enterprise value
• Top Consensus
• Analyst Opinion
• Target price
• Estimates Revisions
• Top ranking ESG
• Environment
• Visibility Ranking
• Stock Screener Home
• Oversold stocks
• Overbought stocks
• Close to resistance
• Close to support
• Accumulation Phases
• Most volatile stocks
• Top Investor Rating
• Top Trading Rating
• Top Dividends
• Low valuations
• All my stocks
• Stock Screener
• Stock Screener PRO
• Portfolio Creator
• Event Screener
• Dynamic Chart
• Economic Calendar
• Our subscriptions
• Our Stock Picks
• Thematic Investment Lists

Xbrane Biopharma AB

Se0007789409, biotechnology & medical research.

• Invitation to presentation of Xbrane Biopharma’s interim report January – March 2024 on May 16, 2024

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on Thursday, May 16th, 2024 , at 09.00 a.m. CET . Xbrane will publish the company’s interim report January – March 2024 , on Thursday, May 16, 2024 , at 8.00 a.m. CET .

Anette Lindqvist , CFO/IR, will present the interim report January – March 2024 , followed by a Q&A session. The presentation will be in English. To attend, please follow the link below:

If you wish to participate via webcast, please use the link below. Via the webcast you can ask written questions.

Xbrane Biopharma Q1 Report 2024 (financialhearings.com)

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

Call Access (financialhearings.com)

Martin Åmark, CEO E: [email protected]

Anette Lindqvist , CFO/IR E: [email protected]

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 26 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Solna, just outside Stockholm . Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com  

Attachments

© Modular Finance, source Nordic Press Releases

Latest news about Xbrane Biopharma AB

Chart Xbrane Biopharma AB

Company Profile

Income Statement and Estimates

Analysts' consensus, quarterly earnings, rate of surprise.

• Stock Market
• XBRANE Stock
• News Xbrane Biopharma AB

Zhukovsky International Airport

Zhukovsky International Airport, formerly known as Ramenskoye Airport or Zhukovsky Airfield - international airport, located in Moscow Oblast, Russia 36 km southeast of central Moscow, in the town of Zhukovsky, a few kilometers southeast of the old Bykovo Airport. After its reconstruction in 2014–2016, Zhukovsky International Airport was officially opened on 30 May 2016. The declared capacity of the new airport was 4 million passengers per year.

Sygic Travel - A Travel Guide in Your Pocket

More interesting places

• Privacy Policy
• STOCK 360° TRAVEL VIDEOS

•  » 

Postleitzahl 140050 - Kraskowo, Oblast Moskau

Karte von Postleitzahl 140050

Stadtviertel, ortsvorwahl.

Unternehmen in Postleitzahl 140050

Primär-Stadt

A CIO canceled a Microsoft AI deal. The reason should worry the entire tech industry.

• A pharma company stopped using Microsoft's Copilot AI tool, with an exec citing high cost and low value.
• The company used Office 365 Copilot for 500 staff and compared it to middle-school presentations.
• Microsoft is mulling repackaging 365 licenses to better monetize AI features amid record spending.

AI models and tools look great when researchers measure success with their own wonky benchmarks. When paying customers try this technology in the real world, things can get ugly.

That's what happened when an IT executive at a pharmaceutical company tried out Microsoft's Copilot AI features, according to a recent research note from Morgan Stanley.

The chief information officer of this pharma company paid extra to have 500 employees use Office 365 Copilot in the fourth quarter of 2023 and first quarter of 2024. This is Microsoft 's much-heralded AI upgrade to its popular suite of productivity software.

After six months, the exec canceled the upgrade because the AI tools weren't good enough to be worth the extra money.

In fact, he compared the slide-generation capability of Microsoft's AI tools to "middle school presentations," according to a transcript of a call with the Morgan Stanley analysts that was included in their research note.

"The price is double," the executive, identified only as Greg, said. "And we really just do not see the value we're getting out of those tools worth double."

The E3 version of Microsoft's 365 software suite costs about $34 per user a month. Adding Copilot AI features costs another $30 per user a month. For 500 employees, that would roughly add an extra $180,000 a year.

These new Microsoft tools are considered some of the premier examples of powerful artificial intelligence in action in the real world. Investors have bid up Microsoft and other big tech shares massively, betting that this product and similar offerings will catch on with paying customers.

If a large pharma company can't see $180,000 of value in these tools, that's a problem that should worry the entire tech industry.

Legal issues with AI meeting summaries

The 365 Copilot AI feature that the IT executive found more compelling was the ability to archive and summarize video meetings on Microsoft's Teams app. But he said his legal team was wary of retaining meeting transcripts, so the pharma company didn't use that feature.

Related stories

"What you're left with are tools that are along the lines of building ChatGPT instead of Word, which I think is marginally useful at best," the exec said. "Building a generative AI slide capability, which really is at the quality of middle school presentations at this point. And then Excel, which is, again, not really something that most people who use spreadsheets would think of using it."

He added that the company would consider adopting Office 365 Copilot for a subset of employees if it cost a fraction of its current price.

Microsoft must recoup big AI investments

The comments follow internal concerns at Microsoft about whether its AI services will create enough value to persuade corporate customers to pay more.

Wall Street is also wondering how Microsoft will recoup its massive AI spending. The company is amassing 1.8 million graphics processing units to build and run AI models and related products. It also has a plan to triple data-center capacity, mainly to handle AI workloads. Its capital expenditure hit a record $14 billion in the most recent quarter. A company spokesperson did not respond to a request for comment.

Microsoft is considering revamping the way it packages 365 software licenses like E3 to try to make more money from AI. The outcomes could include repackaging AI features into existing licenses or creating a more expensive bundle with Copilot AI capabilities, a person with direct knowledge of the plan said.

Do you work at Microsoft or have insight to share?

Contact Ashley Stewart via the encrypted messaging app Signal (+1-425-344-8242) or email ( [email protected] ). Use a nonwork device.

Watch: Volkswagen is using AI to speed up and scale marketing, while also integrating ChatGPT into its vehicles, says CMO Susanne Franz

• Main content

• Company History
• Organization
• Key Opinion Leaders
• Sustainability
• Biosimilars
• Rights Issue 2024
• Ownership Structure
• Share Capital
• Financial Reports
• Presentations
• Press Releases
• Financial Calendar
• Corporate Governance Reports
• Articles Of Association
• General Meeting
• Nomination Committee
• Incentive program

Xbrane to regain full rights to BIIB801, a proposed biosimilar referencing CIMZIA®

Corporate Information

Other Corporate Information

Xbrane Biopharma (publ) ("Xbrane" or the "Company") today announced they will regain full rights to BIIB801 following a decision by Biogen Inc.to terminate the commercialization and license agreement between the companies. All rights to the product will be reverted to Xbrane. An out-licensing process to identify a new partner has been initiated. BIIB801 is a preclinical monoclonal antibody fragment that is a proposed biosimilar referencing CIMZIA® (certolizumab pegol

BIIB801 is the only biosimilar candidate under development referencing Cimzia®

Xbrane has developed BIIB801 based on its patented platform technology enabling high yield production. The platform is especially well suited for antibody fragments expressed in e-coli host cells, which is the case for certolizumab, the active substance in Cimzia®. Thanks to this platform technology and the ability to reach the required production yield for a commercially viable biosimilar, BIIB801 is currently, as per Xbrane’s knowledge, the only biosimilar candidate under development referencing Cimzia® globally. Cimzia® is a TNF inhibitor used in treatment of mainly rheumatoid arthritis and psoriasis with annual sales of about € 2 billion with a niche position in pregnant and breast-feeding women. The production process of the biosimilar candidate is successfully scaled up together with Xbrane’s selected contract manufacturer and production of clinical material is taking place during 2024 enabling initiation of clinical trial in 2025. Analytical similarity is demonstrated and initial scientific advice with both EMA and FDA has been held. The production process enabling the high yield is patented by Xbrane.

Xbrane regain full rights to BIIB801

Xbrane entered into a licensing agreement for BIIB801 with Biogen Inc. in February 2022. Under the terms of the agreement Biogen paid a non-refundable upfront payment of USD 8 million. Biogen has indicated to Xbrane that the termination relates to a recent strategic review. All rights granted to Biogen under the agreement will be terminated and hence the full rights to the program will be retained by Xbrane.

A structured out-licensing process initiated

Xbrane has over the last 12 months received significant inbound interest in the program from potential commercialization partners in case the rights would be regained. Xbrane has initiated a structured out-licensing process with the ambition to find a new development and commercialization partner. Given the program´s uniqueness, Xbrane is optimistic in the possibilities of being successful in this process under an accelerated timeline.

Impact on Xbranes financial position

Xbrane has previously communicated a target to reach positive operational cash-flow in Q1 2025. Positive operational cash-flow is now envisioned to be reached in Q2 2025 and maintained thereafter provided FDA approval of Ximluci® (proposed biosimilar referencing Lucentis®) in Q2 2025 but not including any potential income from BIIB801, XdivaneTM (proposed biosimilar referencing Opdivo®) or other programs. Xbrane communicated in connection with the rights issue in Q1 2024 that, provided successful execution of the business plan, including timely FDA approval for Ximluci® and a secured partnership for Xdivane™, the net proceeds from the rights issue would fulfill the Company’s working capital requirement until Q1 2025. Given the previously communicated delay in FDA approval of Ximluci® and the unforeseen termination of the license agreement with Biogen, Xbrane needs to successfully out-license both XdivaneTM and BIIB801 during coming months to ensure financing until envisioned positive operational cash-flow in Q2 2025. Xbrane is currently in advanced negotiations regarding out-licensing of XdivaneTM and believes an accelerated out-licensing process for BIIB801 is possible given the uniqueness of the program.

Martin Åmark, CEO E: [email protected]

Anette Lindqvist, CFO/IR E: [email protected]

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 26 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit  www.xbrane.com  

This information is information that Xbrane Biopharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-08-01 08:58 CEST.

Attachments